99 related articles for article (PubMed ID: 5947637)
21. The clinical determination of unique effect of potentiation of phenothiazine medication by nylidrin hydrochloride.
Chu J; Doering MF; Fogel EJ
Int J Neuropsychiatry; 1966 Feb; 2(1):53-9. PubMed ID: 5907814
[No Abstract] [Full Text] [Related]
22. [Some forms of reaction to chlorpromazine in mentally retarded patients].
Wasik A
Psychiatr Pol; 1967; 1(1):91-4. PubMed ID: 5597276
[No Abstract] [Full Text] [Related]
23. Intramyocardial lesions in patients dying suddenly and unexpectedly.
Richardson HL; Graupner KI; Richardson ME
JAMA; 1966 Jan; 195(4):254-60. PubMed ID: 4221635
[No Abstract] [Full Text] [Related]
24. Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: an interim report.
Johnson G; Gershon S; Hekimian LJ
Compr Psychiatry; 1968 Nov; 9(6):563-73. PubMed ID: 4883428
[No Abstract] [Full Text] [Related]
25. [The estimate of efficiency of amitriptyline activity in pscyhoses with depressive reactions].
Cwynar S; Nagurska H
Neurol Neurochir Psychiatr Pol; 1965; 15(2):289-91. PubMed ID: 5837690
[No Abstract] [Full Text] [Related]
26. Intermittent phenothiazine therapy with chronic patients.
Zocchi AF; Tourlentes TT; Pollack SL; Haim D
Arch Gen Psychiatry; 1969 Jun; 20(6):726-8. PubMed ID: 5772545
[No Abstract] [Full Text] [Related]
27. [Psychopharmacological therapy in the so-called mentally retarded children with special reference to Encephabol medication].
Jacobs R
Kinderarztl Prax; 1969 Mar; 37(3):111-5. PubMed ID: 5398342
[No Abstract] [Full Text] [Related]
28. Clinical experience with chlorprothixene in disturbed children. A comparative study.
Harman C; Winn DA
Int J Neuropsychiatry; 1966 Feb; 2(1):72-7. PubMed ID: 5907817
[No Abstract] [Full Text] [Related]
29. [Fluorothyl: pharmacological aspect and clinical use].
Villeneuve A
Int Z Klin Pharmakol Ther Toxikol; 1968 Jul; 1(5):389-93. PubMed ID: 4387336
[No Abstract] [Full Text] [Related]
30. [Influence of the seasons on the course and therapeutic results of depressive phases of maniomelancholy (author's transl)].
Sedivec V
Cesk Psychiatr; 1981 Oct; 77(5):326-30. PubMed ID: 7326778
[No Abstract] [Full Text] [Related]
31. [Use of atropine in the treatment of depressive states].
Nazarchuk AG
Vrach Delo; 1980 Aug; (8):90-2. PubMed ID: 7415142
[No Abstract] [Full Text] [Related]
32. Two cases of deep vein thrombosis associated with antipsychotic drug use.
Matsumoto M; Konno T; Tamba K; Abe T; Kato S; Kajii E
Psychiatry Clin Neurosci; 2004 Aug; 58(4):450-1. PubMed ID: 15298663
[No Abstract] [Full Text] [Related]
33. Toxic psychotic syndrome associated with chlorpromazine administration.
Anath JV; Ban TA; Lehmann HE
Can Med Assoc J; 1970 Mar; 102(6):642. PubMed ID: 5437399
[No Abstract] [Full Text] [Related]
34. [Therapy refractory depressive episode in bipolar disorder caused by primary hyperparathyroidism].
Drach LM
Psychiatr Prax; 2001 Mar; 28(2):100-1. PubMed ID: 11305157
[No Abstract] [Full Text] [Related]
35. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
Gallagher P; Watson S; Elizabeth Dye C; Young AH; Nicol Ferrier I
J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098
[TBL] [Abstract][Full Text] [Related]
36. Lithium versus chlorpromazine for manics. Initiative and productivity versus tranquilization hospitalization.
Wittrig J; Coopwood WE
Dis Nerv Syst; 1970 Jul; 31(7):486-9. PubMed ID: 5505577
[No Abstract] [Full Text] [Related]
37. State-dependent changes in the expression levels of NCAM-140 and L1 in the peripheral blood cells of bipolar disorders, but not in the major depressive disorders.
Wakabayashi Y; Uchida S; Funato H; Matsubara T; Watanuki T; Otsuki K; Fujimoto M; Nishida A; Watanabe Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1199-205. PubMed ID: 18430502
[TBL] [Abstract][Full Text] [Related]
38. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
Akiskal HS; Benazzi F; Perugi G; Rihmer Z
J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic and therapeutic strategies in treatment-resistant depression. Introduction and clinical presentations.
O'Reardon JP
CNS Spectr; 2009 Mar; 14(3 Suppl 4):4-6. PubMed ID: 19407713
[No Abstract] [Full Text] [Related]
40. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia.
Mackin P; Gallagher P; Watson S; Young AH; Ferrier IN
Aust N Z J Psychiatry; 2007 Apr; 41(4):321-6. PubMed ID: 17464718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
